5 Key Takeaways

• 1

  Once-daily low-dose prednisolone may provide modest cardiometabolic benefits over thrice-daily hydrocortisone in adrenal insufficiency patients.

• 2

  The trial involved 46 patients and compared prednisolone (2 to 5 mg) with hydrocortisone over two 120-day periods.

• 3

  Prednisolone treatment resulted in slower bone turnover and lower levels of several bone markers compared to hydrocortisone.

• 4

  Patients on prednisolone experienced greater reductions in body weight, BMI, waist circumference, and glycated hemoglobin.

• 5

  No significant differences in subjective health outcomes or overall safety were observed between the two treatments.